Therapeutic Asset Ratings

1,028 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
rc48-adc Non-Small Cell Lung Carcinoma	Guangdong Provincial People's Hospital	P2	CCC (50)
Sacituzumab Tirumotecan Cancer	Convalife (Shanghai) Co., Ltd.	P2	CCC (50)
Sacituzumab Tirumotecan Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (50)
Shr-A2009 Breast Cancer	Fudan University	P2	CCC (50)
T-Dxd Breast Cancer	Peking University Cancer Hospital & Institute	P2	CCC (50)
Trastuzumab Emtansine Colorectal Cancer	Boehringer Ingelheim	P2	CCC (50)
Trastuzumab Emtansine Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (50)
rc88 Advanced Solid Tumours	RemeGen Co., Ltd.	P1/2	CCC (50)
Immunoglobulin G1 [188,412-bis[4-(azidomethyl)-L-phenylalanine]], anti-(human folate receptor ?) (human-Mus musculus monoclonal SP8166 ?1-chain), disulfide with human-Mus musculus monoclonal SP8166 ?-chain, dimer, click reaction product with 3-[[[[4-[[N-[4-(11,12-didehydrodibenz[b,f]azocin-5(6H)-yl)-1,4-dioxobutyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-N,?,?-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl-L-valinamide (1:4) Cancer	Tasly Pharmaceutical Group Co., Ltd	P1/2	CCC (49)
Anti-EGFR Antibody-drug Conjugate MRG003 Non-Small Cell Lung Carcinoma	Anhui Provincial Cancer Hospital	P2	CCC (48)
ARX 788 Breast Neoplasm	Shengjing Hospital	P2	CCC (48)
ARX 788 HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
ARX 788 HER2-positive Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Datopotamab Deruxtecan Breast Neoplasm	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Datopotamab Deruxtecan Her2-Receptor Negative Breast Cancer	Ana C Garrido-Castro, MD	P2	CCC (48)
Datopotamab Deruxtecan HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Datopotamab Deruxtecan Lung Cancer	Latin American Cooperative Oncology Group	P2	CCC (48)
Datopotamab Deruxtecan Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Hepatocellular Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Melanoma	Grupo Español Multidisciplinar de Melanoma	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Metastatic Prostate Carcinoma	University of Utah	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Colorectal Cancer	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Pancreatic Ductal Adenocarcinoma	University of Kansas Medical Center	P2	CCC (48)
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2	CCC (48)
hlx43 Cervical Cancer	Shanghai Henlius Biotech	P2	CCC (48)

Showing 601 to 625 of 1,028 assets

PreviousPage 25 of 42Next